Segment Information (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of segment information - net sales and operating earnings


	Net Sales to External Customers								Operating Earnings
	Three Months				Nine Months				Three Months				Nine Months
	Ended September 30				Ended September 30				Ended September 30				Ended September 30
(in millions)	2020		2019		2020		2019		2020		2019		2020		2019
Established Pharmaceutical Products	$	1,099	$	1,212	$	3,156	$	3,312	$	201	$	281	$	588	$	654
Nutritional Products		1,924		1,874		5,711		5,541		394		414		1,327		1,241
Diagnostic Products		2,640		1,909		6,460		5,655		875		456		1,802		1,356
Medical Devices		3,170		3,065		8,530		9,035		928		958		2,122		2,722
Total Reportable Segments		8,833		8,060		23,857		23,543		2,398		2,109		5,839		5,973
Other		20		16		50		47
Net sales	$	8,853	$	8,076	$	23,907	$	23,590
Corporate functions and benefit plan costs										(129)		(131)		(367)		(332)
Net interest expense										(127)		(143)		(373)		(437)
Share-based compensation (a)										(100)		(94)		(448)		(434)
Amortization of intangible assets										(510)		(484)		(1,624)		(1,453)
Other, net (b)										(111)		(154)		(447)		(480)
Earnings from continuing operations before taxes									$	1,421	$	1,103	$	2,580	$	2,837

(a)	Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net for the three and nine months ended September 30, 2020 and 2019 includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three and nine months ended September 30, 2020 also includes costs related to asset impairments, partially offset by income from the settlement of litigation. Other, net for the nine months ended September 30, 2019 includes charges associated with R&D assets acquired and immediately expensed.